VBI Vaccines Inc. (Nasdaq: VBIV and TSX: VBV) (“VBI”) will host a hepatitis B (“HBV”) Key Opinion Leader meeting on Monday, June 13 at 12:00 PM ET. The event is being held at the Lotte New York Palace in New York City.
The event will feature keynote presentations by Dr. Daniel Shouval, M.D. and Dr. Florian Schödel, M.D., who will discuss new approaches to vaccination against hepatitis B as well as the unmet medical need. In addition, members of the VBI management team will provide an overview of Sci-B-Vac®, a third-generation HBV vaccine that mimics all three viral surface antigens of the hepatitis B virus. Sci-B-Vac is approved in Israel and in 14 other countries and has demonstrated a favorable safety and efficacy profile in over 300,000 patients. Download Presentation PDFAt the time of the event, a live webcast will be available at: http://lifesci.rampard.com/20160613/reg.jsp
Dr. Shouval is a Professor of Medicine and the former Dean of the Faculty of Medicine at the Hebrew University and Hadassah Medical School in Jerusalem, where he established Israel’s first liver unit in 1983. He is a visiting Professor at Albert Einstein College of Medicine and has held similar positions at Harvard Medical School, Massachusetts General Hospital, and the University of Paris. Dr. Shouval currently serves as a standing adviser to the European Viral Hepatitis Prevention Board and the World Health Organization (“WHO”), and has previously served as both President and Chairman of the Educational Committee of the European Association for the Study of the Liver (“EASL”).
Dr. Schödel has more than 20 years of pharmaceutical, biotech industry, and academic experience leading teams in the development of vaccines and biologics. A physician and microbiologist by training, Dr. Schödel holds adjunct faculty appointments at the University of Munich and at the Biodesign Center of ASU. Dr. Schödel’s research has focused on novel recombinant vaccines against diseases including hepatitis B, malaria, and typhoid. He has led the clinical teams responsible for several successful vaccine filings in the U.S., the European Union, and globally, including several pediatric combination vaccines.
The event is intended for institutional investors and sell-side analysts only. If you would like to attend, please contact Mac MacDonald at (212) 915-2567 or via e-mail at email@example.com.
- Event: Hepatitis B Key Opinion Leader Meeting
- Date: Monday, June 13, 2016
- Time: 12:00 PM ET – 1:30 PM ET
- Location: Lotte New York Palace in New York, NY
- Webcast: http://lifesci.rampard.com/20160613/reg.jsp
About VBI Vaccines Inc.
VBI Vaccines Inc. (“VBI”) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac™, a hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac is approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology allows for the development of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (“CMV”) and glioblastoma multiforme (“GBM”). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.
Cautionary Statement on Forward-looking Information
Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation (collectively, “forward-looking statements”) that may not be based on historical fact, but instead relate to future events, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. All statements other than statements of historical fact included in this release are forward-looking statements.
Such forward-looking statements are based on a number of assumptions, including assumptions regarding the successful development and/or commercialization of the company’s products, including the receipt of necessary regulatory approvals; general economic conditions; competitive conditions; and changes in applicable laws, rules and regulations.
VBI cautions the reader that forward-looking statements and information involve known and unknown risks, uncertainties and other factors that may cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements or information contained in this news release and VBI has made assumptions and estimates based on or related to many of these factors.
Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on the company’s current expectations, and the company undertakes no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.
(617) 830-3031 x124
VBI Investor Contact
Director, Corporate Development and Investor Relations
(617) 830-3031 x128